JPS63243034A - Solid agent containing low-melting substance - Google Patents
Solid agent containing low-melting substanceInfo
- Publication number
- JPS63243034A JPS63243034A JP7398087A JP7398087A JPS63243034A JP S63243034 A JPS63243034 A JP S63243034A JP 7398087 A JP7398087 A JP 7398087A JP 7398087 A JP7398087 A JP 7398087A JP S63243034 A JPS63243034 A JP S63243034A
- Authority
- JP
- Japan
- Prior art keywords
- calcium silicate
- substance
- vitamin
- melting point
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002844 melting Methods 0.000 title claims abstract description 16
- 239000000126 substance Substances 0.000 title claims abstract description 16
- 239000007787 solid Substances 0.000 title claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000378 calcium silicate Substances 0.000 claims abstract description 13
- 229910052918 calcium silicate Inorganic materials 0.000 claims abstract description 13
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000008018 melting Effects 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- 239000004503 fine granule Substances 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract description 5
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 3
- 229960000984 tocofersolan Drugs 0.000 abstract description 3
- 239000002076 α-tocopherol Substances 0.000 abstract description 3
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract description 2
- 230000005484 gravity Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000011769 retinyl palmitate Substances 0.000 abstract description 2
- 229940108325 retinyl palmitate Drugs 0.000 abstract description 2
- 235000019172 retinyl palmitate Nutrition 0.000 abstract description 2
- 235000004835 α-tocopherol Nutrition 0.000 abstract description 2
- 230000002745 absorbent Effects 0.000 abstract 1
- 239000002250 absorbent Substances 0.000 abstract 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 11
- 239000010436 fluorite Substances 0.000 description 11
- 239000000284 extract Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000009491 menaquinone-4 Nutrition 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- 229960005481 menatetrenone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】 産業上の利用分野 本発明は低融点物質を含有する固形剤に関する。[Detailed description of the invention] Industrial applications The present invention relates to solid formulations containing low melting point substances.
詳しくは本発明は低融点物質にケイ酸カルシウムを配合
して成る高含量の低融点物質を含有する固形剤に関する
。More specifically, the present invention relates to a solid formulation containing a high content of a low melting point substance, which is formed by blending the low melting point substance with calcium silicate.
発明の背景
従来ビタミンＥやビタミンＥ二／コチン酸エステルのよ
うな油性薬物及びメンフェゴールや生薬エキスなどの低
融点薬物を含有する固形剤の製造に当たっては、軽質無
水ケイ酸などに該薬物を吸着させていた。Background of the Invention Conventionally, in the production of solid preparations containing oil-based drugs such as vitamin E and vitamin E di/cotinic acid esters, and low-melting point drugs such as memphegol and herbal medicine extracts, the drugs have been adsorbed onto light silicic anhydride or the like. was.
このような方法の欠点は例えば錠剤の場合に打錠時にス
ティッキング（ｓｔｉｃｋｉｎｇ）や、キャッピング（
ｃａｐｐｉｎｇ）を生ずることがあり、また硬度不足の
ため実際の生産上において欠けや割れの発生することが
ある。品質上にも問題があった。そのため固形剤におい
て大量の吸着剤を使用しなければならず、したがって薬
物の含量は極めて少量に制限せざるを得なかった。Disadvantages of such methods include, for example, sticking and capping during tablet compression.
capping), and chipping or cracking may occur during actual production due to insufficient hardness. There were also quality issues. Therefore, a large amount of adsorbent must be used in solid preparations, and the drug content must therefore be limited to an extremely small amount.
発明の駐
本発明者らは今回、吸着剤としてケイ酸カルシウムを使
用することにより上記のすべての問題が解決できること
を見出した。すなわち低融点薬物に対して３０重量％以
上のケイ酸カルシウムを配合した場合にスティッキング
やキャッピングを起さず、十分な硬度を有する固形剤が
得られるのである。換言すれば、ケイ酸カルシウムを使
用した場合にケイ酸カルシウムに対して、その約３．３
倍までの薬物を含有させることができるのである。The present inventors have now discovered that all of the above problems can be solved by using calcium silicate as an adsorbent. In other words, when 30% by weight or more of calcium silicate is blended with the low melting point drug, a solid agent that does not cause sticking or capping and has sufficient hardness can be obtained. In other words, when calcium silicate is used, about 3.3
It is possible to contain up to twice as much drug.
本発明において使用されるケイ酸カルシウムは、見掛比
重０．０８〜０，１２を有し、嵩及び吸液量の大きいも
のであり、特に好ましいケイ酸カルシウムは化学式：
％式％
（式中、Ｉ＜ｍ＜２．２＜ｎ＜３である。）で示される
ジャイロライト型特殊ケイ酸カルシウムであり、徳山曹
達株式会社から「フローライトＲ」の商品名で市販され
ているものである。このフローライトＲは粉体であり、
嵩が大きく成形性が良好である。また安全性については
日本薬局方外医薬品コード４６００及び汎用化粧品原料
１−５０に収載されており、米国薬局方（ＮＦ−ＸＶＩ
）のケイ酸カルシウムの規格値にも適合する。The calcium silicate used in the present invention has an apparent specific gravity of 0.08 to 0.12, and has a large volume and liquid absorption. Particularly preferable calcium silicate has the chemical formula: % formula % (in the formula , I<m<2.2<n<3.), and is commercially available from Tokuyama Soda Co., Ltd. under the trade name "Fluorite R". . This Fluorite R is a powder,
It has a large bulk and good moldability. Regarding safety, it is listed in the Japanese Non-Pharmaceutical Drug Code 4600 and General Purpose Cosmetic Ingredients 1-50, and is listed in the United States Pharmacopoeia (NF-XVI
) also meets the standard values for calcium silicate.
本発明の低融点物質上しては、例えばｄ−α−トコフェ
ロール、ｄσ−α−トコフェロール、ｄ−α−酢酸トコ
フェロール、ｄρ−α−酢酸トコフエａ−ｆｉｖ、ｄ（
１−α−ニコチン酸トコフェロール、ビタミンＡパルミ
テート、フィトナジオン、メナテトレノン、ユビデカレ
ノン、メンフェゴール、テブレノンならびにカッコソー
軟エキス、トウキ軟エキス及びセンキュー軟エキスのよ
うな生薬軟エキスなどがある。Examples of the low melting point substances of the present invention include d-α-tocopherol, dσ-α-tocopherol, d-α-tocopherol acetate, dρ-α-tocopherol acetate a-fiv, d(
Examples include tocopherol 1-α-nicotinate, vitamin A palmitate, phytonadione, menatetrenone, ubidecarenone, memphegol, tebrenone, and soft extracts of herbal medicines such as kakkoso soft extract, touki soft extract, and senkyu soft extract.
本発明の固形剤は錠剤、顆粒、カプセル剤、フィルム錠
、糖衣錠、細粒、又は散剤などのような形態であること
ができる。The solid dosage form of the present invention can be in the form of tablets, granules, capsules, film tablets, sugar-coated tablets, fine granules, or powders.
本発明の固形剤（ｊ、他の薬物、無水ケイ酸又はその他
の添加剤を配合することができる。The solid agent of the present invention (j) may contain other drugs, silicic anhydride, or other additives.
次に、実施例を掲げて本発明を更に具体的ｌこ説明する
。Next, the present invention will be explained in more detail with reference to Examples.
３一
実施例 １
ヘンシェルミキサーＦＭ−２５［（株）三井三池製作断
裂コ？こフローライトＲ３６０９を入れ、混合しながら
酢酸ｄＣ−α−トコフェロール３６ｏｇを添加し、フロ
ーライトＲに吸着させた。その後メチルセルロース３６
ｇを添加し、常法にしたがい造粒、乾燥、整粒を行い酢
酸 ｄσ−α−トコフェロールの吸着顆粒を得た。31 Example 1 Henschel Mixer FM-25 [Made by Mitsui Miike Co., Ltd.] This Fluorite R3609 was added, and while mixing, 36 og of dC-α-tocopherol acetate was added and adsorbed onto Fluorite R. Then methyl cellulose 36
g was added thereto, followed by granulation, drying, and granulation according to a conventional method to obtain adsorbed granules of dσ-α-tocopherol acetate.
この顆粒１００部に噴霧乳糖９０部、タルク１ｏ部を添
加して混合し、打錠用粉末を得た。これをロータリー型
打錠機で１錠２００ｍｇとなるように製錠した。90 parts of atomized lactose and 10 parts of talc were added to 100 parts of the granules and mixed to obtain a powder for tabletting. This was tableted using a rotary tablet machine so that each tablet weighed 200 mg.
実施例 ２
フローライトＲを５４０ｇにした点を除いて、実施例１
の手順をくり返した。Example 2 Example 1 except that Fluorite R was 540 g.
The procedure was repeated.
実施例 ３
フローライトＲが２４０９であった点を除いて実施例１
の手順をくり返した。Example 3 Example 1 except that Fluorite R was 2409
The procedure was repeated.
実施例 ４
フローライトＲが１４４ｇであった点を除いて実施例１
の手順をくり返した。Example 4 Example 1 except that Fluorite R was 144 g.
The procedure was repeated.
＝４一
対照例 Ａ
フローライトＲの代りに無水ケイ酸、沈降製、サイロー
ド２４４（商品名） ３６０ｇを使用した点を除いて実
施例１の手順をくり返した。=4 - Control Example A The procedure of Example 1 was repeated except that 360 g of Silicic Anhydride, Cylord 244 (trade name) manufactured by Seikan Co., Ltd., was used instead of Fluorite R.
対照例 Ｂ
フローライトＲの代わりに無水ケイ酸水加物〔カープレ
ックス（商品名））３６ｈを使用した点を除いて実施例
１の手順をくり返した。Control Example B The procedure of Example 1 was repeated except that Fluorite R was replaced by silicic anhydride hydrate (Carplex (trade name)) 36h.
上記のようにして製造した錠剤について、打錠障害発生
の有無を下表に総括して示す。The table below summarizes the presence or absence of tableting failure for the tablets produced as described above.
実施例１並びに対照例Ａ及びＢにおいて得られた錠剤の
硬度（本屋式硬度計による）と打錠圧との関係を図面に
示す。ケイ酸カルシウムの使用によりすぐれた硬度が得
られることがわかる。The relationship between the hardness of the tablets obtained in Example 1 and Control Examples A and B (according to a Honya type hardness tester) and tableting pressure is shown in the drawing. It can be seen that excellent hardness can be obtained by using calcium silicate.
実施例 ５
ｄり一α−Ｍ’ｌトコフェロール５００ｇとフローライ
トＲ１５０ｇとをヘンシェルミキサーＦＭ２５（（株）
三井三池製作所製〕で１０分間混合し、更に適量の水を
加えて細粒状になるまで混合した。Example 5 500 g of d Riichi α-M'l tocopherol and 150 g of Fluorite R were mixed in a Henschel mixer FM25 (Co., Ltd.).
(manufactured by Mitsui Miike Seisakusho) for 10 minutes, and then an appropriate amount of water was added and mixed until the mixture became fine granules.
このものを常法にしたがって乾燥後篩分して３２メツシ
ユから１５０メツシユまでの間の乾燥物を得た。This material was dried in a conventional manner and then sieved to obtain a dry product having a size of 32 to 150 meshes.
このものは日本薬局方の細粒剤規格に適合する粒度分布
であった。This product had a particle size distribution that met the Japanese Pharmacopoeia's fine granule standards.
実施例 ６
実施例１で得た錠剤１０００ｇを常法のパン・コーティ
ング法により下記糖衣液を用いて１錠３６０ｍｇになる
まで糖衣を行い、カルナウバロウにより艶出しを行って
糖衣錠１８００ｇを得た。Example 6 1,000 g of the tablets obtained in Example 1 were sugar-coated using the following sugar-coating solution by a conventional pan coating method until each tablet weighed 360 mg, and then glazed with carnauba wax to obtain 1,800 g of sugar-coated tablets.
糖衣液処方
白 糖 ６００部
タルク ８０部
アラビアゴム末 ２０部
実施例 ７
実施例１で得た錠剤３００ｇを７１イコーター・ミニ〔
（株）フロイント製〕を用いて、下記フィルム液により
フィルムコーティング操作を１錠２１０ｍｇになるまで
行い、フィルム錠を得た。Sugar Coating Solution White Sugar 600 parts Talc 80 parts Gum Arabic powder 20 parts Example 7 300 g of the tablets obtained in Example 1 were added to 71 Ecoater Mini [
(manufactured by Freund Co., Ltd.), film coating was performed using the following film solution until each tablet weighed 210 mg to obtain film tablets.
フィルム液処方
ヒドロキシプロピルメチルセルロース ７５部（信越化
学制、商品名ＴＣ−５Ｒ）
ポリエチレングリコール６０００ ２５部エチ
ルアルコール ５００部実施例 ８
ｄａ−α−ニコチン酸トコフェロール（融点４５℃ニア
−
常温では固体）を約８０℃で過温して液状化し、その５
００ｇとフローライトＲ３００ｍｇとをヘンシェルミキ
サーＦＭ−２５Ｃ（株）三井三池製作所製〕でＩＯ分間
混合し、後は実施例５と同様に操作して日本薬局方の細
粒剤規格に適合する細粒剤を得た。Film liquid formulation Hydroxypropyl methylcellulose 75 parts (Shin-Etsu Chemical, trade name TC-5R) Polyethylene glycol 6000 25 parts Ethyl alcohol 500 parts Example 8 Tocopherol da-α-nicotinate (melting point 45°C near- solid at room temperature) was added to approx. Liquefied by overheating at 80℃, Part 5
00g and 300mg of Fluorite R were mixed for 10 minutes using a Henschel mixer FM-25C (manufactured by Mitsui Miike Seisakusho Co., Ltd.), and then the same procedure as in Example 5 was performed to obtain fine granules that meet the Japanese Pharmacopoeia's fine granule standards. obtained the drug.
図面は実施例１ならびに対照例Ａ及びＢにおいて得られ
た錠剤の硬度と打錠圧力との関係を示すグラフ図である
。The drawing is a graph showing the relationship between the hardness and tableting pressure of the tablets obtained in Example 1 and Control Examples A and B.
Claims (1)
％以上配合して成る固形剤。 ２、低融点物質が融点６０℃以下を有するものである特
許請求の範囲第１項記載の固形剤。 ３、低融点物質が油性薬物である特許請求の範囲第１項
記載の固形剤。 ４、油性薬物がビタミンＥ関連薬物である特許請求の範
囲第３項記載の固形剤。 ５、ビタミンＥ関連物質がビタミンＥ、ビタミンＥ酢酸
エステル又はビタミンＥニコチン酸エステルである特許
請求の範囲第４項記載の固形剤。 ６、錠剤、顆粒、カプセル剤、フィルム錠、細粒又は散
剤の形態にある特許請求の範囲第１項記載の固形剤。[Claims] 1. A solid agent containing 30% by weight or more of calcium silicate based on a low melting point substance. 2. The solid preparation according to claim 1, wherein the low melting point substance has a melting point of 60°C or less. 3. The solid preparation according to claim 1, wherein the low melting point substance is an oily drug. 4. The solid preparation according to claim 3, wherein the oil-based drug is a vitamin E-related drug. 5. The solid preparation according to claim 4, wherein the vitamin E-related substance is vitamin E, vitamin E acetate or vitamin E nicotinate. 6. The solid preparation according to claim 1, which is in the form of a tablet, granule, capsule, film tablet, fine granule or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62073980A JP2626975B2 (en) | 1987-03-30 | 1987-03-30 | Tablets containing low-melting oily substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62073980A JP2626975B2 (en) | 1987-03-30 | 1987-03-30 | Tablets containing low-melting oily substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63243034A true JPS63243034A (en) | 1988-10-07 |
| JP2626975B2 JP2626975B2 (en) | 1997-07-02 |
Family
ID=13533757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62073980A Expired - Lifetime JP2626975B2 (en) | 1987-03-30 | 1987-03-30 | Tablets containing low-melting oily substances |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2626975B2 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11178895A (en) * | 1997-12-22 | 1999-07-06 | Nippon Kayaku Co Ltd | Prevention of tabletting failure during tablet manufacture and manufacture of tablet |
| JPH11302157A (en) * | 1998-04-17 | 1999-11-02 | Eisai Co Ltd | Tablet quickly disintegrating in oral cavity |
| JP2001294533A (en) * | 2000-04-14 | 2001-10-23 | Asahi Beer Yakuhin Kk | Method for producing granulated material and tablet |
| WO2007097333A1 (en) * | 2006-02-20 | 2007-08-30 | Asahi Breweries, Ltd. | Granules, tablets and method of producing the same |
| JP2009518321A (en) * | 2005-12-07 | 2009-05-07 | ニコメド ファーマ エイエス | Pre-compressed calcium-containing compound |
| JP2009137892A (en) * | 2007-12-06 | 2009-06-25 | Asahi Kasei Chemicals Corp | Powder for molding, compression molding composition using the same, and method for producing the powder for molding |
| WO2012091039A1 (en) * | 2010-12-27 | 2012-07-05 | 富田製薬株式会社 | Particulate formulation |
| WO2015099139A1 (en) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Solid preparation comprising tofogliflozin and method for producing same |
| CN112584710A (en) * | 2019-06-06 | 2021-03-30 | 美国华纳国际生物科技股份有限公司 | Self-emulsifying solid dispersion composition for medicine or health care product |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2858215A (en) * | 1956-07-02 | 1958-10-28 | Barnett Lab Inc | Process of preparing vitamin oils in particle form |
| JPS5711911A (en) * | 1980-06-25 | 1982-01-21 | Tsumura Juntendo Inc | Preparation of herb medicine tablet |
| JPS58213073A (en) * | 1982-06-07 | 1983-12-10 | Masatoshi Yamada | Solidification of oily substance |
-
1987
- 1987-03-30 JP JP62073980A patent/JP2626975B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2858215A (en) * | 1956-07-02 | 1958-10-28 | Barnett Lab Inc | Process of preparing vitamin oils in particle form |
| JPS5711911A (en) * | 1980-06-25 | 1982-01-21 | Tsumura Juntendo Inc | Preparation of herb medicine tablet |
| JPS58213073A (en) * | 1982-06-07 | 1983-12-10 | Masatoshi Yamada | Solidification of oily substance |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11178895A (en) * | 1997-12-22 | 1999-07-06 | Nippon Kayaku Co Ltd | Prevention of tabletting failure during tablet manufacture and manufacture of tablet |
| JPH11302157A (en) * | 1998-04-17 | 1999-11-02 | Eisai Co Ltd | Tablet quickly disintegrating in oral cavity |
| JP2001294533A (en) * | 2000-04-14 | 2001-10-23 | Asahi Beer Yakuhin Kk | Method for producing granulated material and tablet |
| JP2009518321A (en) * | 2005-12-07 | 2009-05-07 | ニコメド ファーマ エイエス | Pre-compressed calcium-containing compound |
| WO2007097333A1 (en) * | 2006-02-20 | 2007-08-30 | Asahi Breweries, Ltd. | Granules, tablets and method of producing the same |
| JP2009137892A (en) * | 2007-12-06 | 2009-06-25 | Asahi Kasei Chemicals Corp | Powder for molding, compression molding composition using the same, and method for producing the powder for molding |
| WO2012091039A1 (en) * | 2010-12-27 | 2012-07-05 | 富田製薬株式会社 | Particulate formulation |
| JP5585920B2 (en) * | 2010-12-27 | 2014-09-10 | 富田製薬株式会社 | Particulate preparation |
| WO2015099139A1 (en) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Solid preparation comprising tofogliflozin and method for producing same |
| KR20160101719A (en) | 2013-12-27 | 2016-08-25 | 추가이 세이야쿠 가부시키가이샤 | Solid preparation comprising tofogliflozin and method for producing same |
| EP3482748A1 (en) | 2013-12-27 | 2019-05-15 | Chugai Seiyaku Kabushiki Kaisha | Solid preparations containing tofogliflozin and method for producing the same |
| KR20210082557A (en) | 2013-12-27 | 2021-07-05 | 추가이 세이야쿠 가부시키가이샤 | Solid preparations containing tofogliflozin and process of producing the same |
| CN112584710A (en) * | 2019-06-06 | 2021-03-30 | 美国华纳国际生物科技股份有限公司 | Self-emulsifying solid dispersion composition for medicine or health care product |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2626975B2 (en) | 1997-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960005706B1 (en) | Oral sustained release acetaminophen formulation and the preparation process thereof | |
| JP4446177B2 (en) | Method for producing moisture-resistant orally disintegrating tablets | |
| JP5490347B2 (en) | Formulation for oral administration | |
| HRP20030527A2 (en) | Pharmaceutical compositions comprising amlodipinemaleate | |
| CA2435714C (en) | Fenofibrate tablets | |
| JPS63243034A (en) | Solid agent containing low-melting substance | |
| JP4853818B2 (en) | Solid formulation containing ibuprofen and ambroxol hydrochloride | |
| JPS6019715A (en) | Stable isocarbostyril pharmaceutical preparation | |
| JP2017019869A (en) | Solid pharmaceutical composition | |
| JP6434570B2 (en) | Solid pharmaceutical composition | |
| JP6368830B2 (en) | Solid pharmaceutical composition | |
| RU2326660C1 (en) | Oral pharmaceutical composition memantin (options) and method of preparation (options) | |
| JP3782936B2 (en) | Method for producing a solid pharmaceutical preparation derived from a plant extract | |
| JP2013216701A (en) | Preparation for oral administration | |
| JP4400941B2 (en) | Kampo-containing tablets, Kampo-filled capsules, herbal medicine-containing tablets, herbal medicine-filled capsules, manufacturing method of Kampo-containing tablets, herbal medicine-containing capsules, herbal medicine-containing tablets, and herbal medicine-filled capsules | |
| KR20080080318A (en) | Orally disintegrating tablet comprising fat-soluble substance | |
| RU2694056C2 (en) | Anti-tuberculosis stable pharmaceutical composition in form of dispersible tablet containing granulated isoniazid and granulated rifapentine, and method for preparing it | |
| JPH0225428A (en) | Reduction of bitterness and bitterness reducing composition | |
| EP0599767B1 (en) | Process to prepare water-dispersable tablets containing diclofenac | |
| JPH0797325A (en) | Stable solid pharmaceutical and its production | |
| KR100857061B1 (en) | Tablet containing vaccinium myrtillus extract and preparing method thereof | |
| KR20060119860A (en) | Pharmaceutical composition with improved solubility and fluidity | |
| JP2022130003A (en) | Solid preparation containing chinese medicine extract or vegetable herbal medicine extract, and method for producing the same, and method for improving the ease of disintegration of solid preparation | |
| JP6106359B2 (en) | Solid formulation containing loxoprofen sodium and vitamin B1 | |
| Bertuzzi | Effervescent granulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| EXPY | Cancellation because of completion of term |